A Study of SI-6603 in Patients With Lumbar Disc Herniation

ClinicalTrials.gov ID: NCT02421601

Public ClinicalTrials.gov record NCT02421601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label Study of SI 6603 in Patients With Lumbar Disc Herniation (Phase III)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of SI-6603(Condoliase) in patients with lumbar disc herniation.

Study identification

NCT ID: NCT02421601
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Seikagaku Corporation; Industry
Enrollment: 1,011 participants

Conditions and interventions

Conditions

Interventions

Condoliase Drug

Drug

Eligibility (public fields only)

Age range: 30 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2015 (Type not available)
Primary completion: Feb 2018 (Actual)
Completion: Feb 2018 (Actual)
Last update posted: Mar 23, 2023

2015 – 2018

United States locations

U.S. sites: 30
U.S. states: 15
U.S. cities: 30

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	—	—
Not listed	Phoenix	Arizona	—	—
Not listed	Gold River	California	—	—
Not listed	Laguna Hills	California	—	—
Not listed	Los Gatos	California	—	—
Not listed	Riverside	California	—	—
Not listed	Temecula	California	—	—
Not listed	Greenwood Village	Colorado	—	—
Not listed	Clermont	Florida	—	—
Not listed	Hialeah	Florida	—	—
Not listed	Jacksonville	Florida	—	—
Not listed	Miami	Florida	—	—
Not listed	Miami Gardens	Florida	—	—
Not listed	Naples	Florida	—	—
Not listed	Pinellas Park	Florida	—	—
Not listed	Sarasota	Florida	—	—
Not listed	South Miami	Florida	—	—
Not listed	St. Petersburg	Florida	—	—
Not listed	Winter Park	Florida	—	—
Not listed	Marietta	Georgia	—	—
Not listed	Newnan	Georgia	—	—
Not listed	Bloomington	Illinois	—	—
Not listed	Carmel	Indiana	—	—
Not listed	Shreveport	Louisiana	—	—
Not listed	City of Saint Peters	Missouri	—	—
Not listed	Hartsdale	New York	—	—
Not listed	Eugene	Oregon	—	—
Not listed	Charleston	South Carolina	—	—
Not listed	Plano	Texas	—	—
Not listed	Sandy City	Utah	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02421601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 23, 2023 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02421601 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →